ENGINEERING OF CELL-PENETRATING PEPTIDE-CONJUGATED INTRACELLULAR DELIVERY SYSTEMS - Biologically-Responsive Hybrid Biomaterials - page 227

[72] Kwon, Y.M., et al., “PTD-modified ATTEMPTS system for enhanced asparaginase
therapy: a proof-of-concept investigation,” J Control Release , Vol. 130, No. 3, 2008, pp.
252-8.
[73] Kwon, Y.M., et al., “The ATTEMPTS delivery systems for macromolecular drugs,” Expert
Opin Drug Deliv , Vol. 5, No. 11, 2008, pp. 1255-66.
[74] Massodi, I., et al., “Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-
ELP,” Clin Exp Metastasis , Vol. 26, No. 3, 2009, pp. 251-60.
[75] Moy, P., et al., “Tat-mediated protein delivery can facilitate MHC class I presentation of
antigens,” Mol Biotechnol , Vol. 6, No. 2, 1996, pp. 105-13.
[76] Shibagaki, N., and Udey, M.C., “Dendritic cells transduced with protein antigens induce
cytotoxic lymphocytes and elicit antitumor immunity,” J Immunol , Vol. 168, No. 5, 2002,
pp. 2393-401.
[77] Wang, H.Y., et al., “Induction of CD4(+) T cell-dependent antitumor immunity by TAT-
mediated tumor antigen delivery into dendritic cells,” J Clin Invest , Vol. 109, No. 11, 2002,
pp. 1463-70.
[78] Kabouridis, P.S., et al., “Inhibition of NF-kappa B activity by a membrane-transducing
mutant of I kappa B alpha,” J Immunol , Vol. 169, No. 5, 2002, pp. 2587-93.
[79] Cao, G., et al., “In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein
Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis,” J
Neurosci , Vol. 22, No. 13, 2002, pp. 5423-31.
[80] Khafagy el, S., et al., “Effect of cell-penetrating peptides on the nasal absorption of
insulin,” J Control Release , Vol. 133, No. 2, 2009, pp. 103-8.
[81] Wheeler, D.S., Dunsmore, K.E., and Wong, H.R., “Intracellular delivery of HSP70 using
HIV-1 Tat protein transduction domain,” Biochem Biophys Res Commun , Vol. 301, No. 1,
2003, pp. 54-9.
[82] Eum, W.S., et al., “In vivo protein transduction: biologically active intact pep-1-superoxide
dismutase fusion protein efficiently protects against ischemic insult,” Free Radic Biol Med ,
Vol. 37, No. 10, 2004, pp. 1656-69.
[83] Gallo, G., “Making proteins into drugs: assisted delivery of proteins and peptides into living
neurons,” Methods Cell Biol , Vol. 71, No. 2003, pp. 325-38.
[84] Cornelissen, B., et al., “Cellular penetration and nuclear importation properties of 111In-
labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast
cancer cells,” Nucl Med Biol , Vol. 34, No. 1, 2007, pp. 37-46.
[85] Josephson, L., et al., “High-efficiency intracellular magnetic labeling with novel
superparamagnetic-Tat peptide conjugates,” Bioconjug Chem , Vol. 10, No. 2, 1999, pp.
186-91.
[86] Dodd, C.H., et al., “Normal T-cell response and in vivo magnetic resonance imaging of T
cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles,” J
Immunol Methods , Vol. 256, No. 1-2, 2001, pp. 89-105.
[87] Kaufman, C.L., et al., “Superparamagnetic iron oxide particles transactivator protein-
fluorescein isothiocyanate particle labeling for in vivo magnetic resonance imaging
detection of cell migration: uptake and durability,” Transplantation , Vol. 76, No. 7, 2003,
pp. 1043-6.
[88] Tkachenko, A.G., et al., “Cellular trajectories of peptide-modified gold particle complexes:
comparison of nuclear localization signals and peptide transduction domains,” Bioconjug
Chem , Vol. 15, No. 3, 2004, pp. 482-90.
[89] Zhao, M., et al., “Differential conjugation of tat peptide to superparamagnetic nanoparticles
and its effect on cellular uptake,” Bioconjug Chem , Vol. 13, No. 4, 2002, pp. 840-4.
[90] Pittet, M.J., et al., “Labeling of immune cells for in vivo imaging using magnetofluorescent
nanoparticles,” Nat Protoc , Vol. 1, No. 1, 2006, pp. 73-9.